WHAT THE STUDY ACTUALLY SAYS

A once-weekly dual-receptor drug cleared liver disease in a phase 2b MASH trial

In 381 adults with biopsy-confirmed MASH and stage 2–3 fibrosis, efinopegdutide resolved the disease in most participants at one year. It is a mid-stage trial of a drug that is not approved.

MASH resolution without worsening of fibrosis at week 52Efinopegdutide 7 mg: 63%; Efinopegdutide 10 mg: 61%; Efinopegdutide 4 mg: 56%; Semaglutide 2.4 mg: 53%; Placebo: 13%0%35%70%Efinopegdutide 7 mg63%Efinopegdutide 10 mg61%Efinopegdutide 4 mg56%Semaglutide 2.4 mg53%Placebo13%
MASH resolution without worsening of fibrosis at week 52
GroupValue (%)
Efinopegdutide 7 mg63
Efinopegdutide 10 mg61
Efinopegdutide 4 mg56
Semaglutide 2.4 mg53
Placebo13
MASH resolution without worsening of fibrosis at week 52 Proportion of participants meeting the primary endpoint in each group; placebo is the reference arm [s1]. Source: The Lancet

A once-weekly injectable that acts on two gut-hormone receptors at once resolved metabolic dysfunction-associated steatohepatitis in most of the adults who took it, in a mid-stage trial published in The Lancet [s1]. The drug, efinopegdutide, is not approved, and this is a phase 2b study rather than the larger phase 3 evidence regulators require — but the effect on liver biopsies was large, and the trial included an active comparison with semaglutide, the GLP-1 drug furthest along in the same disease.

Why a dual-receptor drug is being tested in liver disease

Metabolic dysfunction-associated steatohepatitis, or MASH, is the more aggressive form of fatty liver disease: fat in the liver drives inflammation and scarring (fibrosis) that can progress to cirrhosis. Weight loss improves it, which is why drugs in the GLP-1 family are being studied. Efinopegdutide goes a step further — the investigators describe it as a GLP-1–glucagon receptor co-agonist, hitting both receptors with a relative potency balance of roughly 2:1 [s1]. The glucagon arm is thought to act directly on the liver, and the question the trial set out to answer was whether that combination clears disease on biopsy, not just whether it lowers weight.

What the trial did

This was a phase 2b, randomised, double-blind, placebo-controlled study run at 176 academic and community centres across 26 countries [s1]. It enrolled adults aged 18 or older with biopsy-confirmed MASH and stage 2 or stage 3 fibrosis [s1]. Participants were randomly assigned in equal fifths to efinopegdutide at 4 mg, 7 mg or 10 mg, to placebo, or to open-label semaglutide 2.4 mg — all given under the skin once a week [s1]. The programme is registered as NCT05877547 [s2].

The primary endpoint was MASH resolution without worsening of fibrosis at week 52, read from a repeat liver biopsy; a missing end-of-treatment biopsy was counted as failure [s1]. The key secondary histological endpoint was fibrosis improvement of at least one stage without worsening of steatohepatitis [s1].

Between 23 June 2023 and 29 December 2025 the investigators screened 1,704 people and randomly assigned 386 (23%), of whom 381 (99%) received at least one dose and were analysed — 194 (51%) women and 187 (49%) men [s1]. Most had the less advanced of the two fibrosis stages: 239 (63%) had F2 and 142 (37%) had F3, and the mean age was 53 years [s1].

What it found

The disease resolved without fibrosis worsening in 31 of 55 participants (56%) on 4 mg, 31 of 49 (63%) on 7 mg, and 35 of 57 (61%) on 10 mg, against 7 of 53 (13%) on placebo [s1]. The differences versus placebo were large and statistically significant: 43.0 percentage points for 4 mg (95% CI 25.7 to 57.8), 49.5 points for 7 mg (31.4 to 64.2) and 47.8 points for 10 mg (30.7 to 62.0), each with p<0.0001 [s1]. In the semaglutide arm, 26 of 49 (53%) met the same endpoint [s1].

On the harder test — improving fibrosis by at least one stage without worsening the steatohepatitis — the picture was more graded. That occurred in 43% on 4 mg, 52% on 7 mg and 34% on 10 mg, versus 21% on placebo [s1]. The 7 mg difference was clearly significant (30.4 percentage points, 15.4 to 44.3, p<0.0001), the 4 mg difference was significant (21.7 points, 7.1 to 35.7, p=0.0038), but the 10 mg difference did not reach significance (13.0 points, −1.2 to 26.8, p=0.072) [s1]. Semaglutide improved fibrosis in 25% [s1].

The most frequent side effects were gastrointestinal, as with other drugs in the class, and they were most common at the 10 mg dose [s1]. Discontinuations because of side effects also clustered at the top dose: 9 of 79 participants (11%) on 10 mg stopped, against 3–4% on the lower efinopegdutide doses and 1% on placebo [s1]. The authors conclude that the 7 mg dose showed the most favourable benefit-risk profile, improving fibrosis in about half of participants after a year [s1].

How to read it

Three cautions keep this in proportion. First, it is a phase 2b trial — designed to find a dose and a signal, not to confirm a benefit. The higher 10 mg dose was not better than 7 mg on fibrosis and carried more dropouts, so more drug was not more benefit here. Second, the endpoints are biopsy readings at one year; they are the accepted surrogate regulators use, but they are not the same as fewer cases of cirrhosis, liver failure or death, which take years to measure and were not assessed. Third, the study was funded by the drug's maker, Merck Sharp & Dohme [s1]; that does not invalidate a blinded, biopsy-read trial, but it is part of the context.

What to watch

The near-term questions are whether a phase 3 programme confirms the 7 mg result on fibrosis, how efinopegdutide's biopsy effects and tolerability compare head-to-head with semaglutide and the already-filed MASH drugs over longer follow-up, and whether histological resolution eventually tracks with the clinical outcomes that matter. For now, the honest summary is that a dual-receptor drug cleared disease on biopsy in most treated participants, in one well-run mid-stage trial — a strong signal, not an approved treatment [s1].

This article describes clinical-trial results and is not medical advice. Anyone with fatty liver disease should discuss treatment with their own clinician.

Sources

  1. Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2–3 fibrosis: a phase 2b, randomised, placebo-controlled study — The Lancet , November 9, 2026
  2. A Study of Efinopegdutide (MK-6024) in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) (NCT05877547) — ClinicalTrials.gov

More on

Related coverage